

Panel	Intervention	Current strength	Priority
PCC	Definition of disease severity for adults	Consensus recommendation	Low
PCC	Definition of disease severity for children and adolescents	Consensus recommendation	Low
PCC	Monitoring and markers of clinical deterioration	Consensus recommendation	Low
	Disease-modifying treatments		
DMTC	Corticosteroids for adults	Recommended	Moderate
DMTC		Conditional recommendation against	Moderate
DMTC	Corticosteroids for pregnant or breastfeeding women	Recommended	Moderate
DMTC		Conditional recommendation against	Moderate
DMTC	Corticosteroids for children or adolescents	Conditional recommendation against	Moderate
DMTC		Conditional recommendation against	Moderate
DMTC	Remdesivir for adults	Conditional recommendation - Consider using remdesivir for adults hospitalised with COVID-19 who require oxygen but not ventilation.	High
DMTC		Not recommended - Do not use remdesivir for adults hospitalised with COVID-19 who require ventilation.	High
DMTC	Remdesivir for pregnant or breastfeeding women	Conditional recommendation - Consider using remdesivir for pregnant or breastfeeding women hospitalised with moderate to severe COVID-19 who do not require ventilation	High
DMTC		Not recommended	High
DMTC	Remdesivir for children or adolescents	Conditional recommendation against - Use of remdesivir for children or adolescents with COVID-19 outside of a trial setting should not be considered routinely.	High
DMTC	Tocilizumab for adults	Conditional recommendation - Consider using tocilizumab for the treatment of COVID-19 in adults who require supplemental oxygen, particularly where there is evidence of systemic inflammation.	High
DMTC	Tocilizumab for pregnant or breastfeeding women	Conditional recommendation - Consider using tocilizumab for the treatment of COVID-19 for pregnant or breastfeeding women who require supplemental oxygen, particularly where there is evidence of systemic inflammation.	High
DMTC	Tocilizumab for children or adolescents	Conditional recommendation - Consider using tocilizumab for the treatment of COVID-19 in children and adolescents who require supplemental oxygen, particularly where there is evidence of systemic inflammation.	High
DMTC	Sarilumab	Conditional recommendation	Moderate
DMTC	Baricitinib	Conditional recommendation	Moderate
DMTC	Azithromycin	Not recommended	Moderate
DMTC	Colchicine	Not recommended	Moderate
DMTC	Convalescent plasma	Not recommended	Moderate
DMTC	Hydroxychloroquine	Not recommended	Moderate
DMTC	Hydroxychloroquine plus azithromycin	Not recommended	Moderate
DMTC	Interferon β -1a	Not recommended	Moderate
DMTC	Interferon β -1a plus lopinavir-ritonavir	Not recommended	Moderate
DMTC	Lopinavir-ritonavir	Not recommended	Moderate

Panel	Intervention	Current strength	Priority
DMTC	Budesonide	Not recommended outside of clinical trials	Moderate
DMTC	Anakinra	Not recommended outside of clinical trials	Moderate
DMTC	Aprepitant	Not recommended outside of clinical trials	Low
DMTC	Baloxavir marboxil	Not recommended outside of clinical trials	Low
DMTC	Bamlanivimab	Not recommended outside of clinical trials	Low
DMTC	Bromhexine hydrochloride	Not recommended outside of clinical trials	Low
DMTC	Chloroquine	Not recommended outside of clinical trials	Low
DMTC	Combined metabolic cofactor supplementation (CMCS)	Not recommended outside of clinical trials	Low
DMTC	Darunavir-cobicistat	Not recommended outside of clinical trials	Low
DMTC	Dutasteride	Not recommended outside of clinical trials	Low
DMTC	Favipiravir	Not recommended outside of clinical trials	Low
DMTC	Fluvoxamine	Not recommended outside of clinical trials	Low
DMTC	Human umbilical cord mesenchymal stem cells	Not recommended outside of clinical trials	Low
DMTC	Hydroxychloroquine plus azithromycin	Not recommended outside of clinical trials	Low
DMTC	Interferon β -1b (inhaled)	Not recommended outside of clinical trials	Low
DMTC	Interferon β -1b	Not recommended outside of clinical trials	Low
DMTC	Interferon gamma	Not recommended outside of clinical trials	Low
DMTC	Interferon kappa plus trefoil factor 2 (IFN- κ plus TFF2)	Not recommended outside of clinical trials	Low
DMTC	Intravenous Immunoglobulin	Not recommended outside of clinical trials	Low
DMTC	Intravenous Immunoglobulin plus methylprednisolone	Not recommended outside of clinical trials	Low
DMTC	Ivermectin	Not recommended outside of clinical trials	High
DMTC	Ivermectin plus doxycycline	Not recommended outside of clinical trials	Moderate
DMTC	N-acetylcysteine	Not recommended outside of clinical trials	Low
DMTC	Nitazoxanide	Not recommended outside of clinical trials	Low
DMTC	Peginterferon lambda	Not recommended outside of clinical trials	Low
DMTC	Recombinant human granulocyte colony-stimulating factor (rhG-CSF)	Not recommended outside of clinical trials	Low
DMTC	REGN-COV2	Not recommended outside of clinical trials	Moderate
DMTC	Ruxolitinib	Not recommended outside of clinical trials	Low
DMTC	Sofosbuvir-daclatasvir	Not recommended outside of clinical trials	Low
DMTC	Sulodexide	Not recommended outside of clinical trials	Low
DMTC	Telmisartan	Not recommended outside of clinical trials	Low
DMTC	Triazavirin	Not recommended outside of clinical trials	Low
DMTC	Umifenovir	Not recommended outside of clinical trials	Low
DMTC	Vitamin D analogues (calcifediol/cholecalciferol)	Not recommended outside of clinical trials	Low

Panel	Intervention	Current strength	Priority
DMTC	Zinc	Not recommended outside of clinical trials	Low
	Chemoprophylaxis		
DMTC	Hydroxychloroquine for pre-exposure prophylaxis	Not recommended outside of clinical trials	Low
DMTC	Hydroxychloroquine for post-exposure prophylaxis	Not recommended outside of clinical trials	Low
HAC	Respiratory support in adults	Consensus recommendation	
HAC	High-flow nasal oxygen therapy	Conditional Recommendation	Low
HAC		Not recommended	Low
HAC		Conditional Recommendation	Low
HAC		Not recommended	Low
HAC		Conditional Recommendation	Low
Critical	Respiratory management of the deteriorating patient	Consensus recommendation	Low
Critical	Videolaryngoscopy	Conditional Recommendation	Low
Critical	Neuromuscular blockers	Conditional recommendation against	Low
Critical	Positive end-expiratory pressure	Consensus recommendation	Low
Critical	Prone positioning for non-intubated adults	Consensus recommendation	Low
Critical	Prone positioning for intubated adults	Consensus recommendation	Low
Critical	Prone positioning for non-intubated pregnant and postpartum women	Consensus recommendation	Low
Critical	Prone positioning for intubated pregnant and postpartum women	Consensus recommendation	Low
Critical	Recruitment manoeuvres	Consensus recommendation	Low
Critical	ECMO for adults	Conditional Recommendation	Low
Critical	ECMO for pregnant and postpartum women	Consensus recommendation	Low
	Respiratory support in neonates, children and adolescents		
Critical	High-flow nasal oxygen and non-invasive ventilation	Consensus recommendation	Low
Critical	Prone positioning (non-invasive)	Consensus recommendation	Low
Critical	Respiratory management of the deteriorating child	Consensus recommendation	Low
Critical	Prone positioning (mechanical ventilation)	Consensus recommendation	Low
Critical	Positive end-expiratory pressure (PEEP)	Consensus recommendation	Low
Critical	Recruitment manoeuvres	Consensus recommendation	Low
Critical	Neuromuscular blockers	Conditional recommendation against	Low
Critical	High-frequency oscillatory ventilation (HFOV)	Consensus recommendation	Low
Critical	Videolaryngoscopy	Conditional recommendation	Low
Critical	Extracorporeal membrane oxygenation (ECMO)	Consensus recommendation	Low
	VTE Prophylaxis		

Panel	Intervention	Current strength	Priority
PCC	VTE prophylaxis for adults	Conditional recommendation	Moderate
PCC		Conditional recommendation against	Moderate
PCC	VTE prophylaxis for pregnant and postpartum women	Consensus recommendation	Low
PCC		Consensus recommendation	Low
PCC		Consensus recommendation	Low
PCC	VTE prophylaxis for children and adolescents	Consensus recommendation	Low
PCC	Continuation of ACEIs/ARBs in patients with COVID-19	Recommended	Low
PCC	Continuation of ACEIs in postpartum women	Consensus recommendation	Low
PCC	Steroids for people with asthma or COPD with COVID-19	Consensus recommendation	Low
PCC	Oestrogen-containing therapies	Consensus recommendation	Moderate
PCC		Consensus recommendation	Moderate
PCC		Consensus recommendation	Moderate
PCC	Timing of surgery	Conditional recommendation against	Moderate
Preg	Pregnancy and perinatal care		
Preg	Antenatal corticosteroids	Consensus recommendation	Low
Preg	Mode of birth	Conditional Recommendation	Moderate
Preg	Delayed umbilical cord clamping	Consensus recommendation	Low
Preg	Skin-to-skin contact	Consensus recommendation	Low
Preg	Breastfeeding	Conditional Recommendation	Low
Preg	Rooming-in	Conditional Recommendation	Low
Paeds	Child and adolescent care		
Paeds	Intravenous immunoglobulin	Consensus recommendation	Moderate
Paeds	Corticosteroids	Consensus recommendation	Moderate
Paeds	Other immunomodulatory agents	Consensus recommendation	Moderate
Paeds	Aspirin and antithrombotic agents	Consensus recommendation	Moderate
PCC	Management of post-acute COVID-19	N/A	High
PCC	What interventions are effective for managing symptoms of post-acute COVID-19?	Consensus	High
PCC	Are there interventions that reduce the risk of developing new or ongoing symptoms following acute COVID-19?	None	High
PCC	Is there evidence for any rehabilitation strategy to facilitate recovery for patients who have had covid-19 in a primary care setting? If yes, which ones, for whom, for how long?	None	High
PCC	What psychosocial interventions are effective at alleviating stress and/or preventing the development of mental health conditions in people with COVID-19?	None	High
PCC	What is the effect of the COVID-19 vaccination on symptoms post-acute COVID-19?	None	High

Panel	Intervention	Current strength	Priority
-------	--------------	------------------	----------

LEGEND	
PCC	Primary and Chronic Care Panel
DMTC	Disease-Modifying Treatment and Chemoprophylaxis Panel
HAC	Hospital and Acute Care Panel
Critical	Critical Panel
Preg	Pregnancy and Perinatal Care Panel
Paeds	Paediatric and Adolescent Care Panel